Form 4: Immunome CEO Buys 46,511 Shares in Public Offering

Immunome Inc.'s President and CEO, Clay B. Siegall, purchased 46,511 shares of common stock at $21.50 per share in a public offering.

Summary

• Clay B. Siegall, President and CEO of Immunome Inc. (IMNM), acquired 46,511 shares of the company's common stock.
• The transaction occurred on December 18, 2025, at a price of $21.50 per share.
• This purchase was made in connection with Immunome's recently completed underwritten public offering of common stock.
• Following this transaction, Siegall beneficially owns a total of 853,247 shares of Immunome common stock.

Sentiment

Score: 7

Explanation: The insider purchase by the CEO, especially as part of a public offering, generally signals management confidence and can be viewed positively by the market.

Positives

• Insider buying by the President and CEO, Clay B. Siegall, signals confidence in the company's future prospects.
• The purchase price of $21.50 per share aligns management's financial interests directly with those of shareholders.
• The transaction was part of a public offering, indicating the company successfully raised capital to support its operations and growth.

Related Party Transactions

• Clay B. Siegall, President and CEO, purchased 46,511 shares of common stock from Immunome Inc. as part of a public offering.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal of confidence in the company's future performance.
• The public offering itself indicates the company successfully raised capital, which can support ongoing operations and strategic initiatives.

Key Dates

Recommendation

The purchase of shares by the President and CEO, Clay B. Siegall, as part of a public offering, is a positive signal of management's confidence in Immunome Inc.'s prospects. However, a single insider transaction, while noteworthy, is not sufficient to warrant a 'buy' or 'strong buy' recommendation without a deeper analysis of the company's financials, strategic outlook, and market conditions. It reinforces a 'hold' position for existing investors and suggests further due diligence for potential new investors.

Keywords

Immunome Inc., IMNM, Clay B. Siegall, Insider Trading, Stock Purchase, CEO, Public Offering, Common Stock